Guest Contributor

R&D-to-sales ratio for Rx&D members declines for eighth consecutive year to $1B

Guest Contributor
July 22, 2011

Pharmaceutical R&D slumping

The decline in pharmaceutical R&D investment in Canada is accelerating with the latest data showing a 7.4% drop in expenditures by all companies and nearly 12% for those who are members of Canada's Research-Based Pharmaceutical Companies (Rx&D).

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics

Other News

STIC report finds few improvements in Canada's innovation performance

Business, academic and government leaders debate strategies for boosting collaboration

Canadian Space Agency supporting R&D for regenerative and nanomedicine

CIHR and NSERC boost funding for cutting-edge research with commercial potential






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.